To evaluate intravitreal bevacizumab (IVB) injection efficacy for the treatment of chronic, atypical, or recurrent central serous chorioretinopathy (CSC).
Clinical data from 77 eyes of 71 patients with chronic, atypical, or recurrent CSC treated with IVB were retrospectively analyzed. After initial 6-weekly IVB administration until no subretinal fluid remained at the fovea, additional as-needed IVBs were administered, based on optical coherence tomography findings. Best-corrected visual acuity and central retinal thickness (CRT) were analyzed at baseline and 3, 6, 9, and 12 months after initial IVB.
The significant improvement of baseline logarithm of minimum angle of resolution best-corrected visual acuity and CRT at 3 months (both P < 0.001) was maintained throughout the 12-month follow-up period. Best-corrected visual acuity improved significantly in patients with chronic and recurrent CSC, at all time points (all P < 0.05), but not in patients with atypical CSC. The CRT reduction was significant in all subgroups during the follow-up period (all P < 0.05). Definite leakage on initial fluorescein angiography correlated with improved reduction in CRT (P = 0.039).
As-needed optical coherence tomography–based IVB was effective for reducing CRT in patients with chronic, atypical, or recurrent CSC, and for vision improvement in chronic and recurrent CSC over the 1-year follow-up period.
This retrospective case series showed that initial repeated and subsequent, as-needed, intravitreal bevacizumab injection was effective for anatomical and functional improvement in patients with chronic, atypical, or recurrent central serous chorioretinopathy for 12 months.
*Department of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of Korea; and
†Department of Ophthalmology, Armed Forces Capital Hospital, Seongnam, Republic of Korea.
Reprint requests: Ji Hun Song, MD, PhD, Department of Ophthalmology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon 16499, Republic of Korea; e-mail: email@example.com
Presented in part as a poster at the 2015 Annual Meeting of the American Academy of Ophthalmology (AAO), Las Vegas, NV, November 14–17, 2015.
None of the authors has any financial/conflicting interests to disclose.
Y.-R. Chung and J. W. Kim contributed equally to this work.